
Sign up to save your podcasts
Or


Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations.
CME information and select publications here.
 By Dr. Neil Love
By Dr. Neil Love4.9
5656 ratings
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations.
CME information and select publications here.

134 Listeners

318 Listeners

496 Listeners

67 Listeners

30 Listeners

76 Listeners

13 Listeners

17 Listeners

12 Listeners

0 Listeners

115 Listeners

57 Listeners

3,340 Listeners

197 Listeners

44 Listeners

22 Listeners

363 Listeners

188 Listeners

43 Listeners

0 Listeners